NCT01423617

Efficacy and Safety of Zenoctil in Reducing Body Weight

Double-blind, Randomized, Placebo-controlled, Bicentric Study to Evaluate the Safety and Efficacy of Zenoctil in Reducing Body Weight of Overweight Subjects

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: InQpharm Group · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The intention of the study is to evaluate the safety and potential body weight and body fat loss effects of a 12-week treatment with Zenoctil in a randomized, double-blind, placebo-controlled, parallel study conducted in Caucasian subjects. This study will also include a diet plan for each subject, calculated based on gender, age, and energy requirements; and adjusted to be slightly hypocaloric.

Conditions

• Overweight

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Zenoctil	3 tablets 2 times daily
OTHER	Placebo	3 tablets 2 times daily

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-08-26
• Last updated: 2015-04-23
• Results posted: 2015-04-23

Locations

1 site across 1 country: Germany